Holen Sie sich die Stockscreener-App
14.54
4.15%
-0.63
Handel nachbörslich:
14.51
-0.03
-0.21%
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
Funds from operations of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH) - The Globe and Mail
Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher | PharmExec - Pharmaceutical Executive
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - Pharmaceutical Executive
Ultragenyx cashes in Genglycos-derived priority review voucher for $210M - FirstWord Pharma
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Yahoo Finance
Ultragenyx to sell rare PRV for $210 million - The Pharma Letter
Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy? - Yahoo Finance
Form PRE 14A Ultragenyx Pharmaceutical Inc For: 7 October By Investing.com - Investing.com Nigeria
Ultragenyx Pharmaceutical agrees to sell rare pediatric voucher for US$210M - Mugglehead Investment Magazine
Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize - Endpoints News
Ultragenyx shares rise 3.2% after selling FDA p... - Pluang
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9%Here's Why - MarketBeat
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity - TradingView
Ultragenyx (RARE) Stock Rises on $210M Priority Review Voucher S - GuruFocus
Ultragenyx to sell FDA priority review voucher for $210M (RARE) - Seeking Alpha
Ultragenyx to sell rare disease priority review voucher for $210m - Investing.com
Ultragenyx (RARE) Sells Rare Pediatric Disease Priority Review V - GuruFocus
Ultragenyx PharmaceuticalUnder Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih - TradingView
Ultragenyx to Sell Priority Review Voucher for $210 Million; 20% Payable to NIH - TradingView
A voucher that can speed FDA review is set to sell for $210 million. - Stock Titan
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - GlobeNewswire
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million - Proactive financial news
Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc.OSIS - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. (RARE) stock price, news, quote and history - Yahoo Finance UK
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6%Here's Why - MarketBeat
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation - Yahoo Finance
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ultragenyx says EMA validates MPS IIIA application - Mugglehead Investment Magazine
Ultragenyx Announces Marketing Authorisation Application - GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE.MX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Ultragenyx Pharmaceutical Inc. (RARE) Options Chain - Yahoo! Finance Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Operating margin % of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.8%Time to Buy? - MarketBeat
Cash flow from operating activities of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Return on invested capital % of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat - BioSpace
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts - MarketBeat
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval - Investing.com
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
4.63%
7.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):